The finalists will present in front of an international judging committee at BrainTech Israel 2013 Israel’s first brain technology conference, which will take place on October 14-15, 2013 in Tel Aviv.
For IBT official announcement click here
This work recognizes innovation in neuromodulation through the Soterix Medical High-Definition tDCS platform currently in clinical trials at Harvard Medical School. Dr. Abhishek Datta summarizes "For 5 years, SMI has been the standard for innovation in neuromodulation, and this award recognizes the breakthrough of HD-tDCS, the only platform that combines the robustness and portability of tDCS with the targeting of TMS. We are thrilled for this recognition from the BRAIN prize."
BACKGROUND: High-Definition tDCS (HD-tDCS) is an exclusive Neuromodulation technology developed by Soterix Medical Inc. Invented at The City College of New York, it is the only technology platform that allows tolerated non-invasive delivery of therapeutic current to desired brain regions. As a result, HD-tDCS offers potential for safe and effective treatment of neuropsychiatric disorders not possible with any other technology. HD-tDCS is made possible through innovations in electrode design allowing safe and tolerated passage of current through proprietary “High-Definition” electrodes, individualized brain current-flow modeling and through patented targeting algorithms indicating how to place and energize HD-electrodes on the head.
At Soterix Medical Inc., Engineering Serving Humanity means that we're committed to bring the most advanced medical technology into the hands of people who need it. The commitment underpins everything we do.